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Abstract
Low plasma fibrinogen level is common after cardiopulmonary bypass (CPB). Current sub-
stitution practice with fibrinogen concentrate generally follows a single measurement and
cut-off values from the literature, whereas early postoperative endogenous fibrinogen kinet-
ics is incompletely described and widely disregarded. The aim of this study was to determine
the short-term recovery pattern of plasma fibrinogen after CPB weaning. Our hypothesis
was that in the absence of surgical bleeding, CPB-induced hypofibrinogenemia would
resolve spontaneously and predictably within a few hours. In a prospective, observational
study of 26 patients undergoing conventional CPB (cCPB) or minimally invasive extracorpo-
real circulation (MiECC), Clauss fibrinogen level (C-FIB) was determined at 10 closely
spaced time points after protamine administration. Primary endpoint was the time to recov-
ery of post-CPB fibrinogen levels to1.5 g/L. C-FIB reached its nadir after protamine
administration corresponding to 62 ± 5% (mean ± SD) of the baseline level after cCPB and
68 ± 7% after MiECC (p = 0.027 vs. cCPB). C-FIB recovered spontaneously at a nearly con-
stant rate of approximately 0.08 g/L per hour. In all patients, C-FIB was1.5 g/L at 4 hours
and2.0 g/L at 13 hours after CPB weaning. Following cardiac surgery with CPB and in the
absence of surgical bleeding, spontaneous recovery of normal endogenous fibrinogen lev-
els can be expected at a rate of 0.08 g/L per hour. Administration of fibrinogen concentrate
triggered solely by a single-point measurement of low plasma fibrinogen some time after
CPB is not justified.
Introduction
Fibrinogen reaches critically low levels during acute bleeding. [1] A close association has been
reported between hypofibrinogenemia and severe post-cardiopulmonary bypass (CPB)
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bleeding. [2–6] Consequently, monitoring fibrinogen levels and function and algorithm-based
substitution with fibrinogen concentrate or fresh frozen plasma (FFP) is recommended.
[2,3,7–11] However, variation in the recommended tests, their exact timing, and published
thresholds for substitution with exogenous fibrinogen sources render fibrinogen substitution
practices quite inconsistent at present. Some authors have even challenged the indication for
fibrinogen substitution. [12]
Fibrinogen is also an acute phase protein with plasma levels that rapidly increase in
response to tissue trauma or inflammation. [13] As early as one day after CPB surgery, normal
or even supranormal fibrinogen levels are regularly observed and induce a prothrombotic situ-
ation. [14–16] Sparse data are available describing the spontaneous development of endoge-
nous plasma fibrinogen during the first few hours after CPB, whereas the early
pharmacokinetics and effects of exogenous fibrinogen concentrate are much better docu-
mented. [17]
Reduction of fibrinogen levels after CPB is a physiologically expectable phenomenon. How-
ever, recommendations for exogenous fibrinogen substitution are often based on an early
plasma fibrinogen measurement at only one point after CPB weaning. [11] Thus, knowledge
of spontaneous plasma fibrinogen recovery during the initial hours after CPB appears to be a
basic requirement for rational post-CPB coagulation therapy and specifically for factor substi-
tution. Particularly in patients with mild post-CPB hypofibrinogenemia, this knowledge may
justify watchful waiting and prevent costly overtreatment with exogenous fibrinogen sources.
The primary aim of this study was to closely monitor the time course of endogenous plasma
fibrinogen during the first 24 hours after cardiac surgery with CPB. Second, we quantified the
influence of CPB-induced hemodilution on endogenous fibrinogen decline and recovery by
comparing conventional CPB (cCPB) and CPB with a reduced priming volume (minimally
invasive extracorporeal circulation, MiECC) in a prospectively planned sub-analysis. Our
hypothesis was that hypofibrinogenemia associated with hemodilution rather than bleeding
would resolve spontaneously within a few hours after weaning from CPB.
Methods
This prospective, observational study investigated patients who underwent cardiac surgery
with CPB between November 12, 2015, and July 29, 2016, at a tertiary referral hospital. Ethical
approval (No. 193/15) was provided by the Cantonal Ethical Committee on September 22,
2015. The study protocol was registered with the US National Institutes of Health
(NCT02605330, www.ClinicalTrials.gov). All study measures were performed according to the
Declaration of Helsinki. The manuscript adheres to the statement of the EQUATOR Network
(www.equator-network.org).
Elective adult patients scheduled for cardiac surgery with CPB for either isolated coronary
artery bypass grafting (CABG), isolated aortic valve replacement (AVR), or ascending aorta
replacement (AAR) with hypothermic circulatory arrest (HCA) were studied. The inclusion
criteria were patients above 18 years of age who signed an informed consent. The exclusion
criteria were emergency or redo surgery, anticoagulant medication other than acetylsalicylic
acid within 14 days preceding surgery, a preoperative plasma fibrinogen concentration below
the lower limit of the institutional laboratory reference of 1.75 g/L, known coagulation disor-
ders, a hemoglobin level less than 100 g/L, renal insufficiency with an estimated glomerular fil-
tration rate<60 mL/min/1.73 m2, affiliation with Jehovah’s Witnesses, participation in
another trial, or intraoperative supplementation with any plasma product.
All patients received general anesthesia in accordance with institutional standards. Periop-
erative monitoring included American Society of Anesthesiologists standard monitoring,
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invasive arterial and central venous pressure, transesophageal echocardiography, and pro-
cessed EEG. Cardiac surgery was performed through median sternotomy. CABG was per-
formed exclusively using MiECC (Maquet AG, Rastatt, Germany). For the AVR and AAR
procedures, a cCPB circuit (Maquet AG) was employed. The main differences between
MiECC and cCPB were as follows: 1) the total amount and composition of the priming volume
(MiECC: 600 mL of lactated Ringer’s solution and 5000 IU of unfractionated heparin; cCPB:
1000 mL of lactated Ringer’s solution, 500 mL of hydroxyethyl starch (HES, 130/0.4), and
10000 IU of heparin); 2) the type of driving pump (MiECC: centrifugal pump and cCPB: roller
pump); and 3) the processing method used for shed blood and residual pump blood. In
MiECC, shed blood was recovered and filtered into a reservoir using an automated suction
device (Cardiosmart AG, Muri, Switzerland) designed to minimize air entrainment and
then returned to the venous line. In cCPB, shed blood was filtered and returned to the venous
reservoir via a roller pump. Neither the MiECC nor the cCPB tubing was heparin-coated.
The extracorporeal flow rate was set to 2.0 L/min/m2 of body surface area (MiECC) or to
2.4 L/min/m2 (cCPB). The nasopharyngeal temperature was maintained between 32˚C and
36˚C in CABG and AVR. In AAR, hypothermia was induced to a bladder temperature of
28˚C. Cardioplegic arrest was achieved using a single dose of 100 mL of crystalloid cardiople-
gia (Cardioplexol1, Bichsel AG, Interlaken, Switzerland), and maintained by high potassium
cold blood cardioplegia (Buckberg Solution, Bichsel AG, Switzerland). The anticoagulation
regimen consisted of an IV bolus of heparin (MiECC: 400 IU/kg and cCPB: 500 IU/kg) prior
to aortic cannulation, with the aim of an activated clotting time >480 sec (kaolin-activated
HR-ACT, ACT II Plus, Medtronic Inc., Minneapolis, MN, USA). All patients received a bolus
of tranexamic acid (30 mg/kg) followed by continuous infusion of 15 mg/kg/hour until sternal
closure. No topical hemostasis techniques (e.g., agents containing fibrinogen or thrombin)
were used. After weaning from CPB, heparin was neutralized with protamine chloride in a
1:1 ratio to the initial heparin dose. In MiECC, residual pump blood was completely reinfused
into the patient prior to heparin neutralization. In cCPB, residual blood was processed (Med-
tronic Autolog, Medtronic Inc., Minneapolis, MN, USA) and re-transfused as an autologous
red cell concentrate.
According to Ranucci, an increased a priori risk of bleeding was assumed if the duration of
CPB was expected to exceed 90 minutes, patient age was>65 years, or the serum creatinine
level was >1.36 mg/dL. [18] Perioperative bleeding was defined according to Dyke [19] and
rated as severe in case of delayed sternal closure, re-exploration, pericardial tamponade, post-
operative chest tube drainage of more than 1000 mL/12 hours and if transfusion of more
than 5–10 units of packed red blood cells (RBC) or FFP was necessary within the first postop-
erative day.
Data collection
Data were stored on a departmental research platform (Labkey, Seattle, WA, USA). Fibrinogen
was measured using the Clauss method (Clauss fibrinogen, C-FIB) and using fibrin-based
thrombo-elastometry (FIBTEM-MCF assay, ROTEM1, TEM International GmbH, Munich,
Germany). Whole blood was serially sampled in citrated plastic containers (Monovette, Sar-
stedt AG, Nu¨mbrecht, Germany) at defined time points as follows: baseline level (pre-CPB
value) before anesthesia induction; AodX, five minutes after aortic declamping; Protamine, five
minutes after protamine administration; and T1, T2, T3, T4, T6, T8, T12, T18, and T24 at 1, 2,
3, 4, 6, 8, 12, 18, and 24 hours after protamine administration, respectively. All samples were
immediately sent to the laboratory, pre-heated to 37˚C, and analyzed within 15 minutes.
C-FIB was determined using the Multifibren U reagent (Dade Behring, Liederbach, Germany)
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on a BCS-XP coagulometer (Siemens Healthcare, Marburg, Germany). For FIBTEM, tissue
factor was used as the activator, and cytochalasin D was added for platelet inhibition. To mini-
mize user-dependent variability, all coagulation and viscoelastic testing was performed by the
hemostasis laboratory.
Study endpoints
The primary endpoint was the post-CPB recovery time of the Clauss fibrinogen concentration
(i.e., from 5 minutes after protamine administration to the time point when the Clauss fibrino-
gen levels surpassed a threshold of1.5 g/L). The secondary endpoints included the associa-
tion of hypofibrinogenemia with hemodilution and hypothermia, the post-CPB fibrinogen
nadir, the time to recovery to the pre-CPB value, and recovery patterns of FIBTEM-MCF.
Statistical analysis
Demographic and procedure-related variables were analyzed with contingency table analysis
or nonparametric ANOVA as appropriate (Sigma Plot for Windows, version 12.2; Systat Soft-
ware Inc., Germany). A proportional decrease in C-FIB and hemoglobin after CPB was quanti-
fied as the ratio of the respective concentration measured at Protamine to the ratio measured
at baseline. Due to the non-normal distributions of the ratios and the log differences, this anal-
ysis was based on a Wilcoxon signed rank test, and comparisons were made using the Mann-
Whitney test. Statistical analysis of the post-CPB course of C-FIB was performed in R, version
3.3.0. [20] C-FIB data pertaining to surgery type were fitted for separate linear mixed-effects
models, with time as a fixed-effect covariate and a random effect for each patient. The random
effects for a particular patient were the deviations in the intercept and slope of that patient’s
C-FIB time trend. The two random effects were considered non-correlated, which was con-
firmed by model comparison using the likelihood ratio test. The linear regression model was
fitted to un-transformed and log-transformed data, reporting Wald-type confidence interval.
Additionally, the influence of the baseline C-FIB level, the estimated preoperative weight-
based plasma volume and the fluid administered during CPB on C-FIB at Protamine were
assessed using linear regression models. Since the primary endpoint of this study was purely
descriptive, a sample size calculation was not performed. P values <0.05 were considered
significant.
Data are presented as numbers (percentages), means ± standard deviations, medians (25th;
75th percentiles) or minimum and maximum (min/max) values.
Results
Overall, 87 patients were assessed for eligibility. Forty-eight patients were excluded preopera-
tively and 13 intraoperatively. Twenty-six patients fulfilled the inclusion criteria and were ana-
lyzed (Fig 1).
Demographic and preoperative data are listed in Table 1. The procedural data and basic
outcomes are summarized in subsequent sections of this table. Due to the use of MiECC for
perfusion, CABG patients were exposed to the smallest CPB priming volume, the lowest
amount of Ringer’s infusion, and no HES during CPB. Overall, 10 of the 26 patients (38%) ful-
filled the preoperative criteria for an increased bleeding risk according to the definition of
Ranucci [18]
The transfusion incidence with allogeneic red blood cell concentrates (RBC) was 3/26. One
patient received RBC during CPB, and another two patients were transfused during their
intensive care unit (ICU) stay. None of the patients received FFP, platelets, fibrinogen, or any
other factor concentrate (exclusion criteria). During their ICU stay, the cumulative
Fibrinogen recovery after cardiac surgery
PLOS ONE | https://doi.org/10.1371/journal.pone.0201647 August 3, 2018 4 / 14
mediastinal drainage loss after 6 and 12 hours amounted to medians of 180 and 300 mL,
respectively. Thus all patients, including those assumed pre-operatively to be at an increased
risk of bleeding, [18] were in postoperative bleeding categories 0 (insignificant) or 1 (mild).
[19] After only 24 hours, the CABG/MiECC patients had accumulated a slightly higher drain-
age loss than the other groups (p = 0.02 vs. cCPB). This was because one patient in the CABG
Fig 1. Patient flow diagram. CABG = coronary artery bypass grafting; AVR = aortic valve replacement; AAR = ascending aorta replacement;
HCA = hypothermic circulatory arrest. n indicates number of patients.
https://doi.org/10.1371/journal.pone.0201647.g001
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Table 1. Patient demographics, procedural data and outcomes.
Procedural data
CPB duration (min) 80 (62;115) 69 (57;92) 73 (61;101) 130 (111;141) 0.008
Cross clamp time (min) 52 (38;75) 42 (34;60) 49 (37;67) 82 (62;105) 0.04
HCA duration (min) - - - - - - - - - 12 (10;15) - - -
Lowest temperature (˚C) 33 (31;34) 33 (33;34)† 34 (33;34) †† 27 (24;28) †† <0.001
CPB prime (ml) - - - 600 1500 1500 <0.001
Tranexamic acid (g) 2.2 (1.9;2.4) 2.2 (1.7;2.8) 1.9 (1.7;2.2) 2.2 (2.0;4.3) 0.11
Heparin dose (kIU) 39 (35;45) 35 (30;48) 40 (34;45) 42 (39;48) 0.06
On CPB, infused volume
RBC (U) 0/2 0/0 0/0 0/2 0.03
Lactated Ringer’s (ml) 1957 (1513;2412) 1402 (1215;1950) 2019 (1696;2497) 2423 (2051;2846) 0.004
HES 130/0.4 (ml) 0/500 0/0 0/500 0/500 <0.001
Pre-, post-CPB volume
RBC (U) 0/0 0/0 0/0 0/0 1.00
FFP (U) 0/0 0/0 0/0 0/0 1.00
Platelets (U) 0/0 0/0 0/0 0/0 1.00
ARBC (ml) 216 (0;347) 0 (0;0) 310 (219;430) 348 (252;538) <0.001
Lactated Ringer’s (ml) 2074 (1275;3047) 2700 (1821;3071) 2075 (1795;2746) 1688 (1123;2320) 0.25
HES 130/0.4 (ml) 0/0 0/0 0/0 0/0 1.00
ICU, infused volume
RBC (U) 0/4 0/2 0/2 0/0 0.48
FFP (U) 0/0 0/0 0/0 0/0 1.00
Platelets (U) 0/0 0/0 0/0 0/0 1.00
Lactated Ringer’s (ml) 3489 (2145;5978) 3497 (2402;5979) 4262 (2047;6684) 3173 (1660;4006) 0.47
HES 130/0.4 (ml) 0/0 0/0 0/0 0/0 1.00
Drainage, 6 h (ml) 180 (150;275) 262 (150;312) 150 (120;362) 165 (142;187) 0.31
Drainage, 12 h (ml) 300 (230;470) 412 (295;512) 250 (210;575) 260 (200;330) 0.14
Drainage, 24 h (ml) 525 (397;735) 712 (537;762) 510 (387;812) 355 (250;465) 0.02
ICU LOS (days) 0.9 (0.9;1.0) 0.9 (0.8;1.0) 1.0 (0.9;1.1) 0.9 (0.9;0.9) 0.06
In-house mortality, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 1.00
All Patients
(n = 26)
CABG
(n = 10)
AVR
(n = 10)
AAR
(n = 06)
P
Value
Demographics
Male sex (n, %) 20 (77) 8 (80) 8 (80) 4 (66) 0.80
Age, y 67 ± 11 67 ± 11 70 ± 12 61 ± 6 0.12
BMI (kg/m2) 27 (24;29) 28 (24;31) 27 (24;29) 28 (25;31) 0.68
CAS > 70% 2 (8) 1 (10) 1 (10) 0 (0) 0.81
COPD (n, %) 5 (19) 3 (30) 0 (0) 2 (33) 0.15
Diabetes (n, %) 2 (8) 2 (20) 0 (0) 0 (0) 0.23
Preoperative laboratory
Hemoglobin (g/L) 137 (129;147) 135 (129;147) 142 (131;149) 131 (115;140) 0.39
Platelets (G/L) 190 (175;232) 187 (182;225) 174 (148;225) 224 (195;265) 0.14
Fibrinogen (g/L) 2.8 (2.5;3.1) 3.0 (2.5;3.6) 2.9 (3.1;2.1) 2.7 (2.4;2.9) 0.47
(Continued)
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group experienced transient hemodynamic instability and was treated with transfusion of 2
units of RBC postoperatively. No differences between groups were found regarding transfused
blood products, incidence of new infections, thrombotic events, or in-house mortality.
Primary endpoint
The perioperative nadir of the C-FIB was observed five minutes after protamine administra-
tion (Protamine), at which time the C-FIB had decreased to 64.3 ± 7% of baseline (Fig 2).
Fibrinogen was significantly better preserved with MiECC (at Protamine: MiECC, 67.8 ± 7%
vs. cCPB, 62.1 ± 5%; p = 0.027).
C-FIB significantly increased throughout the subsequent 24 hours (Fig 3). Patients under-
going surgery on MiECC had significantly higher endogenous plasma fibrinogen levels during
the first four hours after heparin reversal than patients perfused with cCPB (p = 0.022). The
post-CPB recovery of the C-FIB over time was fitted with linear regression models. The mean
Clauss fibrinogen (all patients) increased after Protamine at a nearly constant rate of 0.083 g/L
per hour (95% CI, 0.076 to 0.091; R2 = 0.988, p<0.0001), corresponding to an hourly recovery
of 5% of the fibrinogen level present at Protamine. Surgery-specific rate estimates of the Clauss
fibrinogen increase were 0.078 g/L per hour for CABG (0.061 to 0.095), 0.081 g/L per hour for
AVR (0.070 to 0.094), and 0.095 g/L per hour for AAR (0.076 to 0.115); no between-group dif-
ferences were observed (p = 0.371).
The post-CPB recovery times of the C-FIB levels (i.e., from Protamine to the time point at
which the levels surpassed the thresholds of1.5 g/L or2.0 g/L) were determined from the
individual datasets. Post-CPB, 5/26 patients (19%) had fibrinogen levels <1.5 g/L, and 18/26
(69%) patients had levels<2.0 g/L. All patients had levels above 1.5 g/L within 4 hours and
above 2.0 g/L within 13 hours after heparin reversal.
Secondary endpoints
Between the baseline measurement at induction of anesthesia and the Protamine time point,
the C-FIB course differed depending on the type of surgery and the type of CPB. The smallest
decrease to a median of 2.15 g/L (1.86;2.39) was observed for CABG at the time of heparin
reversal, whereas the C-FIB remained at 1.5 g/L or higher in all these patients. The AVR and
AAR showed lower nadirs of the median 1.71 g/L (1.51;1.98) and 1.46 g/L (1.40;1.51), respec-
tively (AVR vs. AAR: n.s.). Thus, at the end of CPB, the fibrinogen levels were significantly less
depressed for MiECC than for cCPB (p = 0.001). Recovery to the C-FIB baseline occurred
within a median time of 11.2 hours (9.2;16.5) from heparin reversal, with no significant differ-
ences between the types of surgery (p = 0.860) or CPB (p = 0.854). CPB-related hemodilution
from an asanguineous prime and fluid administered during CPB reduced the hemoglobin
Table 1. (Continued)
FIBTEM-MCF (mm) 19 (16;21) 20 (17;21) 18 (15;22) 19 (17;20) 0.78
CABG = coronary artery bypass grafting; AVR = aortic valve replacement; AAR = ascending aorta replacement; BMI = body mass index; CAS = carotid artery stenosis;
COPD = chronic obstructive pulmonary disease; FIBTEM-MCF fibrin-based thromboelastometry; CPB = cardiopulmonary bypass; HCA = hypothermic
cardiocirculatory arrest; RBC = red blood cells; FFP = fresh frozen plasma; ARBC = autologous red blood cells; HES = hydroxyethyl starch; ICU = intensive care unit;
ICU LOS = intensive care unit length of stay; KIU = kilo international units; U = unit (corresponds to 275 mL);
†nasopharyngeal temperature;
††core temperature. Data are numbers (percent), mean ± standard deviation, median (25th; 75th) or minimum and maximum (min/max) values.
indicates comparison of CABG/AVR/AAR with contingency table analysis or Kruskal-Wallis one-way ANOVA on Ranks where appropriate.
https://doi.org/10.1371/journal.pone.0201647.t001
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concentration (Hb) in all patients to 76 ± 6% of the baseline at Protamine, with no difference
between MiECC and cCPB (p = 0.542). During the same period, the C-FIB de-creased to
64 ± 7% of the baseline (p<0.001 vs. Hb).
The C-FIB nadir at Protamine was mainly determined by the fibrinogen levels prior to CPB
and to a lesser degree by the preoperative weight-based patient plasma volume. An asangui-
neous fluid load during CPB had a weak negative effect (Table 2).
FIBTEM-MCF patterns prior to, during and after CPB were generally correlated with those
of Clauss fibrinogen. Post-CPB, 4/26 patients (15%) had a FIBTEM-MCF <10 mm. At heparin
Fig 2. Fibrinogen concentration at the sampling points and changes in relation to time point Protamine. Clauss fibrinogen concentration in all
patients during the observation period (upper graph), and relative post-CPB change as percent difference from levels at time point Protamine (lower
graph). In the upper graph the light grey shaded area indicates the period of surgery. Time on CPB is shaded dark grey. The red horizontal line indicates
Clauss fibrinogen at 1.5 g/L. Note that true time intervals increase between sequence points T1 and T24.
https://doi.org/10.1371/journal.pone.0201647.g002
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reversal, the median FIBTEM-MCF was 14 mm (9;21). Overall, FIBTEM-MCF had a larger
variance but was significantly correlated with Clauss fibrinogen (r = 0.810; p<0.001). Among
the three types of surgery, FIBTEM-MCF in CABG remained significantly higher in the post-
CPB period than in AVR (difference of means, 2.9 mm) and AAR (difference of means,
2.0 mm) (each p<0.001 vs. CABG; AVR vs. AAR, difference of means, 0.9 mm, p = 0.115).
Consequently, MiECC was consistently associated with a higher FIBTEM-MCF than cCPB
(difference of means, 2.6 mm, p< 0.001). FIBTEM-MCF at heparin reversal was significantly
Fig 3. Clauss fibrinogen increase after weaning from CPB, according to surgery type. Clauss fibrinogen measurements over time, starting at the
time point Protomine. The comprehensive plots show all patients, with the three types of surgery represented by different symbols. Predictions based on
the fixed effects of the three respective linear mixed-effects models are superimposed.
https://doi.org/10.1371/journal.pone.0201647.g003
Table 2. Patient- and CPB-related factors influencing clauss fibrinogen levels and FIBTEM-MCF at Protamine.
R 95% CI p-value
Clauss fibrinogen Fibrinogen at <Pre-CPB> 0.76 0.56 to 0.96 < 0.0001
Estimated plasma volume 0.28 0.01 to 0.56 0.045
Fluid administered on CPB -0.09 -0.18 to 0.00 0.04
FIBTEM-MCF FIBTEM-MCF at <Pre-CPB> 0.91 0.64 to 1.18 < 0.0001
Estimated plasma volume 0.21 -0.23 to 0.65 0.33
Fluid administered on CPB -0.15 -0.27 to -0.03 0.015
Linear regression models, log-transformed data. Estimated coefficients (R), 95% Wald-type confidence intervals (CI), and p-values from a t distribution.
https://doi.org/10.1371/journal.pone.0201647.t002
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correlated with baseline FIBTEM-MCF and was negatively associated with asanguineous fluid
load during CPB (Table 2).
The sample size did not have sufficient power to discriminate the effects of CPB duration or
the lowest temperature on post-CPB C-FIB and FIBTEM-MCF. Clauss fibrinogen and FIB-
TEM-MCF after Protamine were not correlated with postoperative chest drain output.
Discussion
The main finding of this prospective study in adults undergoing elective on-pump cardiac sur-
gery for either isolated coronary artery bypass grafting, isolated aortic valve replacement, or
ascending aorta replacement with hypothermic circulatory arrest (HCA) is that endogenous
plasma fibrinogen increases from its nadir at the time of heparin reversal at a fast and nearly
constant rate of approximately 0.08 g/L per hour during the subsequent 24 hours. All patients
had fibrinogen levels at or above 1.5 g/L within 4 hours and at or above 2.0 g/L within 13
hours of heparin reversal. Thus, the results confirm our initial hypothesis that hypofibrinogen-
emia resolves spontaneously within a few hours after CPB and heparin reversal.
Previous studies in cardiovascular surgery have reported that fibrinogen levels initially fall
to nearly 50% after CPB [4,14,21–24] and recover to baseline or above after the first postopera-
tive day, independent of whether an exogenous fibrinogen concentrate has been administered.
[16,17,25] The typical decrease in plasma fibrinogen has been mainly attributed to hemodilu-
tion [22,26] as a consequence of using asanguineous fluid to prime the CPB circuit and for vol-
ume resuscitation. [27] Our results confirm the role of CPB-induced hemodilution as a major
contributor to immediate post-CPB hypofibrinogenemia. Consequently, during the initial
four hours after heparin reversal, we observed better preservation of plasma fibrinogen with
MiECC than cCPB due to less hemodilution from the prime.
Fibrinogen substitution is recommended for bleeding patients. [11] However, predicting
individual patients’ risks of significant or even severe non-surgical bleeding for the first few
hours following CPB has proven difficult both pre-operatively and at CPB weaning. [16,18]
This difficulty occurs because clinical bleeding assessments remain at least partially subjective
and arbitrary and do not produce unequivocal results even with substantial efforts towards
standardization. [16,25] Additionally, the universal definition of perioperative bleeding relies
on longitudinal assessment of cumulative chest drainage, which is necessarily retrospective,
and on treatment interventions, which are not guided by universal protocols. [19] These diffi-
culties may explain why early laboratory-guided administration of fibrinogen concentrate in
randomized controlled studies of cardiovascular patients at presumed high risk of bleeding has
not been proven effective in terms of a clinically relevant reduction of blood loss, transfusion,
or adverse outcomes to date. [16,25] Our data demonstrate that, if fibrinogen substitution is
either laboratory-guided or point-of-care (POC)-guided, the time point of measurement is,
due to the fast recovery rate, essential. There is a marked difference in the results depending
on whether measurements are performed just after CPB or at ICU admission. The exact time
point of measurement is not delineated in all studies.
Numerous studies have been performed in vitro, in animals, and in humans with the aim of
preventing or treating coagulopathies associated with the dilution or loss of endogenous
fibrinogen by exogenous supplementation of fibrinogen concentrate. These studies have gen-
erally succeeded in increasing the plasma fibrinogen levels for a short time but have not consis-
tently reduced postoperative blood loss or allogeneic transfusion. [10,16,28–35] In a
randomized trial that targeted a plasma fibrinogen level of 2.5 g/L in high-risk cardiac surgery
patients, administration of fibrinogen concentrate in bleeding patients did not result in a sig-
nificant reduction in intraoperative blood loss compared to a placebo.[25] Similarly to our
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findings, the nadir of plasma fibrinogen occurred at the end of CPB, with a spontaneous recov-
ery towards ICU admission and at 24 hours thereafter even in the group without exogenous
fibrinogen substitution. The mean plasma fibrinogen was 1.7 g/L at the end of CPB and 3.1 g/L
24 hours after placebo infusion, without an increased bleeding tendency compared to that of
the group receiving fibrinogen concentrate. [25] Similarly, Rahe-Meyer et al. described a
fibrinogen concentration of 1.9 g/L at skin closure in their saline placebo group, and recovery
to 3.2 g/L within 24 hours. No increased bleeding was seen in patients who did not receive the
fibrinogen concentrate compared to those in the control group. [16] Notably, nearly 75% of
patients in both of these RCTs would have been classified post hoc as having only insignificant
or mild bleeding according to the universal definition [19] based on the 12-hour chest drain-
age loss data (IQR), regardless of the treatment allocation. Similarly, our study sample also
included patients with a predicted high bleeding risk (38%), but 25/26 did not even bleed mod-
erately (class 0 or 1 only). [19] No FFP or platelet concentrate was required in our series, and
only two patients (8%) received two units of allogeneic RBC each during their ICU stay. The
C-FIB nadir level after protamine administration was not predictive of the subsequent chest
drain output, with a median of 300 mL in the first 12 postoperative hours. This finding sup-
ports the notion that hemodilution-induced nadirs of Clauss fibrinogen similar to those
observed in our study do not justify fibrinogen substitution per se.
Ample evidence shows a statistical association between low plasma fibrinogen and
increased bleeding after cardiac surgery. [2–6] However, this association is neither always
causal nor always unidirectional. Additionally, fibrinogen concentrate substitution did not
ameliorate bleeding tendency. Surgical or thrombopenic bleeding may cause or aggravate
hypofibrinogenemia and vice versa, and mutual causation may vary during a difficult postop-
erative course. Therefore, recent guidelines for severe post-CPB bleeding recommend mainte-
nance of the C-FIB in a range from 1.5 to 2.0 g/L.,[11]
In cases of severe hemodilution, an even higher level of2.0 g/L is suggested to promote
optimal clot formation. [36] Nevertheless, there is a lack of data and consensus in many areas,
such as the trigger and target fibrinogen levels for various patient groups and clinical scenarios
(e.g., in less-than-severe bleeding, in obstetrics or vascular surgery and for various laboratory
and viscoelastic POC tests).
Furthermore, uncertainty still exists concerning the optimal timing for both lab sampling
and treatment with fibrinogen concentrate and even concerning the adequate dose required to
prevent or stop post-CPB bleeding. [9] For instance, a Clauss fibrinogen target of 2.8 g/L has
been advocated for pre-emptive substitution. [6,9,16,18] Pre-emptive substitution of fibrino-
gen concentrate even prior to CPB was also ineffective regarding bleeding and transfusion
requirements. [14] Our results and those of others do not provide any evidence to recommend
pre-emptive targeting of high fibrinogen levels. [16,25] The early kinetics described in our
study also suggest that even the timing of fibrinogen sampling after CPB will influence deci-
sion making and dosing if pre-emptive thresholds are used in the absence of significant bleed-
ing. In agreement with our findings, other studies also estimate the recovery rate of fibrinogen
at 100 mgL-1h-1 between the end of CPB and 24 h thereafter in patients without administration
of exogenous concentrate, [16] and at 130 mgL-1h-1 in patients receiving FFP but not fibrino-
gen concentrate after CPB. [17] Plasma fibrinogen is known to return to normal or even to
reach supranormal levels within 24 hours independent of exogenous supplementations.
[17,37] Our data show an approximate linearity of spontaneous fibrinogen recovery during
these 24 hours.
Nevertheless, the study has some limitations. It is a small, single-center, descriptive series of
elective patients. The surgical and perfusion management followed institutional routines. The
use of specific perfusion circuits and priming fluids, antifibrinolytics, shed blood recovery, and
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surgical hemostasis techniques may have influenced the fibrinogen kinetics and thus limited
external validity. Additionally, only 38% of patients in our cohort were at high risk of bleeding
risk, and the bleeding rate was low. However, data from other groups studying complex car-
diovascular surgery with a high bleeding risk have indicated that patients without exogenous
fibrinogen replacement experience comparable post-CPB fibrinogen concentrations and
bleeding activity than those with substantial substitution of fibrinogen concentrate, and similar
recovery of fibrinogen levels that reach or surpass the pre-operative baseline on the first post-
operative day. [16,17,25]
In conclusion, this study provides new insights into the fibrinogen substitution practice of
cardiac surgery patients. Our exploratory findings suggest that in the absence of active bleed-
ing, low plasma fibrinogen concentration may be tolerated after CPB weaning since plasma
fibrinogen levels recover fast and spontaneously at a nearly constant rate. Thus, in our opinion,
exogenous fibrinogen substitution may be reserved for patients with active non-surgical bleed-
ing accompanied by laboratory evidence of hypofibrinogenemia. Especially in patients with
mild or insignificant post-CPB bleeding, a “wait-and-see” approach appears to be better justi-
fied than administration of exogenous fibrinogen based on a presumed bleeding risk and a sin-
gle-point laboratory measurement. Since our results have been obtained in a small and
narrowly defined patient cohort, our study remains descriptive and is not confirmatory. Our
findings should therefore be considered only as proof of concept at this time. Our conclusions
need further validation and confirmation, e.g., by ongoing and future randomized multicenter
trials.
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